280Bio Inc. has divulged compounds acting as GTPase KRAS wild-type and mutant inhibitors reported to be useful for the treatment of cancer.

Researchers at Leiden University Medical Center and Universiteit Leiden have synthesized anthracyclins reported to be useful for the treatment of cancer.

Haisco Pharmaceutical Group Co. Ltd. has disclosed quinazolinone derivatives acting as poly(ADP-ribose) polymerase 14 (PARP-14; ARTD8) inhibitors reported to be useful for the treatment of cancer, atopic dermatitis and autoimmune disease.

Quanta Therapeutics Inc. has gained IND clearance from the FDA for QTX-3544, an oral multi-KRAS inhibitor with G12V-preferring activity and dual ON/OFF state.

Compass Therapeutics Inc. has announced a new drug candidate, CTX-10726, a novel tetravalent PD-1 x VEGF-A bispecific antibody.

Researchers from China Medical University reported the synthesis and preclinical evaluation of novel PAK4 inhibitors.

Yuhan Corp., Oscotec Inc. and Genosco Inc. were three companies with Asian ties to reap benefit from Johnson & Johnson’s stellar top-line Mariposa study results, wherein J&J’s Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) combo regimen beat out Astrazeneca plc’s standard of care in non-small-cell lung cancer (NSCLC).